The German

Krach Institute for Tech Diplomacy at Purdue Unveils World’s First Tech Diplomacy Academy, Pioneering a New Era of Global Leadership

Retrieved on: 
火曜日, 4月 30, 2024
Education, Technology, White House, Federal Government, State, Local, Security, Training, Other Defense, Defense, Internet, Public Policy, Government, Continuing, Science, Partnership, ARI, Public diplomacy, Veritas Capital, German Marshall Fund, Purdue University, Knowledge, Diplomacy, Semiconductor, The German, United, Assistant, NYCU, Civilization, Security Commission, Computer science and engineering, The Business Council, Comprehension, National Chengchi University, Artificial intelligence, Freedom, Engineering, Australian Strategic Policy Institute, Multimedia, Child, Lead, Tech, Hoover Institution, Policy, Authoritarianism, University, Curriculum, STEM, Krach, NCCU, Commissioner, ASPI, Quad, Renewable energy

Pioneered by the Krach Institute, Tech Diplomacy is a groundbreaking category that integrates technology, commercial and foreign policy expertise to guide the trajectory of trusted tech toward advancing freedom, security and prosperity worldwide.

Key Points: 
  • Pioneered by the Krach Institute, Tech Diplomacy is a groundbreaking category that integrates technology, commercial and foreign policy expertise to guide the trajectory of trusted tech toward advancing freedom, security and prosperity worldwide.
  • View the full release here: https://www.businesswire.com/news/home/20240430522409/en/
    Krach Institute launches Tech Diplomacy Academy (Graphic: Business Wire)
    “Technology shapes every facet of our personal and professional lives, and the destiny of nations,” said Keith Krach, former Under Secretary of State, and Co-founder and Chairman of the Krach Institute for Tech Diplomacy at Purdue.
  • “With the launch of the Tech Diplomacy Academy, we are not merely responding to this reality; we are shaping it.
  • To join the Tech Diplomacy Academy and see what others are saying, please visit TechDiplomacyAcademy.org .

EQS-News: GANÉ Global Balanced Fund becomes GANÉ Value Event Fund

Retrieved on: 
水曜日, 3月 13, 2024
Person, Sale, Annual report, Communication, Federal Financial Supervisory Authority, WPIG, EUR, AG, The German, Partners Capital, MSCI, KVG, Section 2, Value, Reproduction, Bank

Aschaffenburg, February 20, 2024 - In the coming days, the fund management company GANÉ will change the investment concept of the GANÉ Global Balanced Fund, which was launched in December 2023 under the umbrella of GANÉ Investment-AG with sub-funds, from a defensive balanced fund to an offensive balanced fund.

Key Points: 
  • Aschaffenburg, February 20, 2024 - In the coming days, the fund management company GANÉ will change the investment concept of the GANÉ Global Balanced Fund, which was launched in December 2023 under the umbrella of GANÉ Investment-AG with sub-funds, from a defensive balanced fund to an offensive balanced fund.
  • In addition, the fund name will be changed to GANÉ Value Event Fund.
  • Universal-Investment as external KVG and BN & Partners Capital AG as liability umbrella together with GANÉ ensure that all regulatory requirements are fulfilled for the GANÉ Value Event Fund.
  • A decision on the re-establishment of a defensive balanced fund along the lines of the GANÉ Global Balanced Fund will be made in the foreseeable future.

EQS-News: Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024

Retrieved on: 
水曜日, 3月 13, 2024
Person, Sale, Annual report, Communication, Federal Financial Supervisory Authority, WPIG, The German, Partners Capital, Section 2, Reproduction

Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024

Key Points: 
  • Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024
    The issuer is solely responsible for the content of this announcement.
  • Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024
    Aschaffenburg, March 12, 2024.
  • From 2 April 2024, the GANÉ Global Balanced Fund will bear the name “GANÉ Value Event Fund”.
  • The fund was originally launched in December 2023 under the umbrella of GANÉ Investment-AG with sub-funds.

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
火曜日, 2月 27, 2024
Gynaecology, Culture, Blood, Urology, Gastroenterology, CRC, FIT, Internal medicine, The German, Practitioner, Congress, Colorectal cancer, DNA, Cancer, Pharmaceutical industry

This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.

Key Points: 
  • This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • This effort is aimed at increasing brand awareness and establishing ColoAlert® as a key component in medical practices for CRC screening.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

EQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
木曜日, 3月 7, 2024
Gynaecology, Culture, Medicine, Blood, Urology, Gastroenterology, CRC, FIT, Conference, Internal medicine, The German, Practitioner, Congress, Colorectal cancer, DNA, Cancer, Pharmaceutical industry

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Key Points: 
  • Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    BERKELEY, US – MAINZ, Germany – February 27th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its participation as an exhibitor at the esteemed Gynecology Congress (‘Gynäkologie und Geburtshilfe aktuell’) in Stuttgart, Germany, on March 1st.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
木曜日, 2月 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
木曜日, 2月 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

mbiomics Appoints Seasoned Microbiome Expert Christopher Weidenmaier as Chief Scientific Officer

Retrieved on: 
火曜日, 10月 24, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Principal, Host, Harvard Medical School, CSO, Therapy, Conditional sentence, Doctor of Philosophy, Directorate of Research and Civil Affairs, Division, The German, University, Culture, Infection, Hospital, Coronavirus Scientific Advisory Board, Antibiotics, Microbiology, Hygiene

mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).

Key Points: 
  • mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).
  • Dr. Weidenmaier will contribute nearly 20 years of experience in the microbiome and infectious diseases fields and lead the company’s discovery and development efforts as they establish a pipeline of complex microbiome ecosystems product candidates.
  • Over the course of his career, Dr. Weidenmaier has successfully developed and led R&D efforts for next-generation microbiome products.
  • The appointment will strategically expand the mbiomics’ leadership team on its mission to harness the full potential of the microbiome to restore health and overcome disease.

NordLocker introduces file residency feature: How could it help your business?

Retrieved on: 
金曜日, 7月 21, 2023
NordLocker, EEA, Policy, Gramm–Leach–Bliley Act, Privacy, Article, Government, GLBA, The German, European, GDPR, Roger Hawkins (drummer), Music, Cryptocurrency, EU

Some governments offer more advantageous taxation for a business ensuring a significant part of its operations stay within the country.

Key Points: 
  • Some governments offer more advantageous taxation for a business ensuring a significant part of its operations stay within the country.
  • A business may choose to include data residency in its policy for transparency about data storage.
  • Also, German laws have specific data residency regulations for financial records, employment contracts, customer data, medical records, and legal documents.
  • In order to migrate their files and change their data residency, NordLocker users need to contact support or their account manager.

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

Retrieved on: 
火曜日, 3月 7, 2023
Royal, National academy, DNA, Alvan, Harvard Medical School, Science, Merck, Dana–Farber Cancer Institute, JANUVIA, Chromosome, Roivant Sciences, DNA repair, Institute of technology, Cell, Therapy, Technical University of Munich, Schering-Plough, Drug discovery, Human Proteome Organization, Proteomics, University, Research, Analytical and Bioanalytical Chemistry, Radiation therapy, UCB, FRSC, Cancer, Royal Society, SAB, Susan, AbbVie, United States Air Force Scientific Advisory Board, Patient, GSK, National Academy of Medicine, British Mass Spectrometry Society, The German, Pharmaceutical industry, Chemistry, Medicine

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).
  • Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
  • “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant.
  • “I am thrilled to welcome our new Scientific Advisory Board members.